SARS-CoV-2 Clinical Trial
— VIRCHILLDOfficial title:
Comparison of SARS-CoV-2, AdenoVIRus and Rhinovirus Infection of the Respiratory Epithelium in CHILdren vs. the eLDerly
The objective of the VIRCHILLD project is to identify age-related modifications of the bronchial epithelium physiology that account for differences in the response and susceptibility to respiratory viruses. Epidemiology and cell-based data show that respiratory virus infections differentially affect children, adults or the elderly populations. The current worldwide pandemic of SARS-CoV-2 clearly highlighted this notion with a large part of the deaths occurring in the elderly population and very few deaths amongst children. This may be linked to a decreased transmission and/or viral load with SARS-CoV-2 in children compared to adults and elderly. Less in the public eye is the observation that other major respiratory virus targeting the bronchial epithelium (BE) such as rhinovirus (RV) and adenovirus (AdV) cause important clinical feature in children and have a much lower incidence in adults and the elderly populations, which is the opposite to the situation with SARS-CoV-2. Based on this remarkable discrepancy between respiratory viruses the investigators hypothesize that intrinsic age-controlled properties of the respiratory epithelium under resting physiological conditions determine virus susceptibility and virus propagation.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | April 28, 2025 |
Est. primary completion date | April 28, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 17 Years |
Eligibility | Inclusion Criteria: For pediatric patients requiring research-specific bronchial brushing: - Child under 18 years old, - Requiring bronchoscopy as part of routine care - Having informed and signed consent from the holders of parental authority For pediatric patients whose bronchial brushing will be carried out as part of their care and for those whose surgical waste will be collected for research: - Child under 18 years old, - Requiring as part of routine care bronchoscopy and brushing or bronchial fibroscopy under general anesthesia or surgical resection/lobectomy - Having expressed their non-opposition to their child's participation in research For adult patients: - Man or woman - Aged 18 or over - Requiring as part of the care, thoracic surgery such as lobectomy, pneumonectomy or lung transplantation in the Thoracic Surgery Department of Haut Lévêque du Chu Hospital in Bordeaux or inclusion in the TUBE study, described below. - having received an information note and not having objected to their participation in the research Exclusion Criteria: - No affiliation or non-beneficiary of a social security system - During a period of relative exclusion compared to another protocol - Patient born before 36 weeks of amenorrhea - Patient with a documented history of pulmonary fibrosis, primary pulmonary hypertension, cystic fibrosis, pulmonary malformation or chronic viral infections (hepatitis, HIV). - Patient with any dental, nasopharyngeal or bronchial infection with fever (> 38°C) requiring systemic antibiotics in the previous 4 weeks |
Country | Name | City | State |
---|---|---|---|
France | Bordeaux University Hospital | Bordeaux |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bordeaux |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | number of viral particles - Rhinovirus - Children -24 | number of viral particles produced at the apical level after 24 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from children | after 24 hours of infection | |
Primary | number of viral particles - Adenovirus - Children -24 | number of viral particles produced at the apical level after 24 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from children | after 24 hours of infection | |
Primary | number of viral particles - SARS-CoV-2 - Children-24 | number of viral particles produced at the apical level after 24 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from children | after 24 hours of infection | |
Primary | number of viral particles - Rhinovirus - Adults-24 | number of viral particles produced at the apical level after 24 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from adults | after 24 hours of infection | |
Primary | number of viral particles - Adenovirus - Adults-24 | number of viral particles produced at the apical level after 24 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from adults | after 24 hours of infection | |
Primary | number of viral particles - SARS-CoV-2 - Adults-24 | number of viral particles produced at the apical level after 24 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from adults | after 24 hours of infection | |
Primary | number of viral particles - Rhinovirus - elderly-24 | number of viral particles produced at the apical level after 24 hours of infection ( Rhinovirus) by epithelia reconstituted in-vitro from samples from elderly people | after 24 hours of infection | |
Primary | number of viral particles - Adenovirus - Elderly-24 | number of viral particles produced at the apical level after 24 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from elderly people. | after 24 hours of infection | |
Primary | number of viral particles - SARS-CoV-2 - Elderly-24 | number of viral particles produced at the apical level after 24 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from elderly people. | after 24 hours of infection | |
Secondary | number of viral particles - Rhinovirus - Children-48 | number of viral particles produced at the apical level after 48 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from children | after 48 hours of infection | |
Secondary | number of viral particles - Rhinovirus - Children-72 | number of viral particles produced at the apical level after 72 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from children | after 72 hours of infection | |
Secondary | number of viral particles - Rhinovirus - Children-96 | number of viral particles produced at the apical level after 96 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from children | after 96 hours of infection | |
Secondary | number of viral particles - Rhinovirus - Children-168 | number of viral particles produced at the apical level after 168 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from children | after 168 hours of infection | |
Secondary | number of viral particles - Adenovirus - Children -48 | number of viral particles produced at the apical level after 48 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from children | after 48 hours of infection | |
Secondary | number of viral particles - Adenovirus - Children -72 | number of viral particles produced at the apical level after 72 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from children | after 72 hours of infection | |
Secondary | number of viral particles - Adenovirus - Children -96 | number of viral particles produced at the apical level after 96 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from children | after 96 hours of infection | |
Secondary | number of viral particles - Adenovirus - Children -168 | number of viral particles produced at the apical level after 168 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from children | after 168 hours of infection | |
Secondary | number of viral particles - SARS-CoV-2 - Children-48 | number of viral particles produced at the apical level after 48 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from children | after 48 hours of infection | |
Secondary | number of viral particles - SARS-CoV-2 - Children-72 | number of viral particles produced at the apical level after 72 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from children | after 72 hours of infection | |
Secondary | number of viral particles - SARS-CoV-2 - Children-96 | number of viral particles produced at the apical level after 96 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from children | after 96 hours of infection | |
Secondary | number of viral particles - SARS-CoV-2 - Children-168 | number of viral particles produced at the apical level after 168 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from children | after 168 hours of infection | |
Secondary | number of viral particles - Adenovirus - Adults-48 | number of viral particles produced at the apical level after 48 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from adults | after 48 hours of infection | |
Secondary | number of viral particles - Adenovirus - Adults-72 | number of viral particles produced at the apical level after 72 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from adults | after 72 hours of infection | |
Secondary | number of viral particles - Adenovirus - Adults-96 | number of viral particles produced at the apical level after 96 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from adults | after 96 hours of infection | |
Secondary | number of viral particles - Adenovirus - Adults-168 | number of viral particles produced at the apical level after 168 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from adults | after 168 hours of infection | |
Secondary | number of viral particles - Rhinovirus - Adults-48 | number of viral particles produced at the apical level after 48 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from adults | after 48 hours of infection | |
Secondary | number of viral particles - Rhinovirus - Adults-72 | number of viral particles produced at the apical level after 72 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from adults | after 72 hours of infection | |
Secondary | number of viral particles - Rhinovirus - Adults-96 | number of viral particles produced at the apical level after 96 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from adults | after 96 hours of infection | |
Secondary | number of viral particles - Rhinovirus - Adults-168 | number of viral particles produced at the apical level after 168 hours of infection (Rhinovirus) by epithelia reconstituted in-vitro from samples from adults | after 168 hours of infection | |
Secondary | number of viral particles - SARS-CoV-2 - Adults-48 | number of viral particles produced at the apical level after 48 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from adults | after 48 hours of infection | |
Secondary | number of viral particles - SARS-CoV-2 - Adults-72 | number of viral particles produced at the apical level after 72 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from adults | after 72 hours of infection | |
Secondary | number of viral particles - SARS-CoV-2 - Adults-96 | number of viral particles produced at the apical level after 96 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from adults | after 96 hours of infection | |
Secondary | number of viral particles - SARS-CoV-2 - Adults-168 | number of viral particles produced at the apical level after 168 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from adults | after 168 hours of infection | |
Secondary | number of viral particles - Rhinovirus - elderly-48 | number of viral particles produced at the apical level after 48 hours of infection ( Rhinovirus) by epithelia reconstituted in-vitro from samples from elderly people | after 48 hours of infection | |
Secondary | number of viral particles - Rhinovirus - elderly-72 | number of viral particles produced at the apical level after 72 hours of infection ( Rhinovirus) by epithelia reconstituted in-vitro from samples from elderly people | after 72 hours of infection | |
Secondary | number of viral particles - Rhinovirus - elderly-96 | number of viral particles produced at the apical level after 96 hours of infection ( Rhinovirus) by epithelia reconstituted in-vitro from samples from elderly people | after 96 hours of infection | |
Secondary | number of viral particles - Rhinovirus - elderly-168 | number of viral particles produced at the apical level after 168 hours of infection ( Rhinovirus) by epithelia reconstituted in-vitro from samples from elderly people | after 168 hours of infection | |
Secondary | number of viral particles - Adenovirus - Elderly-48 | number of viral particles produced at the apical level after 48 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from elderly people. | after 48 hours of infection | |
Secondary | number of viral particles - Adenovirus - Elderly-72 | number of viral particles produced at the apical level after 72 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from elderly people. | after 72 hours of infection | |
Secondary | number of viral particles - Adenovirus - Elderly-96 | number of viral particles produced at the apical level after 96 hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from elderly people. | after 96 hours of infection | |
Secondary | number of viral particles - Adenovirus - Elderly-168 | number of viral particles produced at the apical level after 168hours of infection (Adenovirus) by epithelia reconstituted in-vitro from samples from elderly people. | after 168 hours of infection | |
Secondary | number of viral particles - SARS-CoV-2 - Elderly-48 | number of viral particles produced at the apical level after 48 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from elderly people. | after 48 hours of infection | |
Secondary | number of viral particles - SARS-CoV-2 - Elderly-72 | number of viral particles produced at the apical level after 72 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from elderly people. | after 72 hours of infection | |
Secondary | number of viral particles - SARS-CoV-2 - Elderly-96 | number of viral particles produced at the apical level after 96 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from elderly people. | after 96 hours of infection | |
Secondary | number of viral particles - SARS-CoV-2 - Elderly-168 | number of viral particles produced at the apical level after 168 hours of infection (SARS-CoV-2 ) by epithelia reconstituted in-vitro from samples from elderly people. | after 168 hours of infection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04527471 -
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
|
Phase 2 | |
Recruiting |
NCT05584202 -
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
|
Phase 2 | |
Completed |
NCT04579549 -
Repeat Testing for SARS-CoV-2
|
N/A | |
Active, not recruiting |
NCT05547243 -
A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China
|
N/A | |
Recruiting |
NCT04613310 -
PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19)
|
N/A | |
Recruiting |
NCT04747574 -
Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection
|
Phase 1 | |
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Terminated |
NCT04447404 -
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
|
Phase 2 | |
Withdrawn |
NCT04388709 -
Interferon Lambda Therapy for COVID-19
|
Phase 2 | |
Active, not recruiting |
NCT05550142 -
A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China
|
N/A | |
Completed |
NCT04620798 -
Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students
|
N/A | |
Active, not recruiting |
NCT05547256 -
A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China
|
N/A | |
Completed |
NCT04452604 -
Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
|
||
Completed |
NCT04561102 -
Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
|
||
Completed |
NCT05366322 -
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
|
||
Terminated |
NCT04958304 -
Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
|
||
Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
Completed |
NCT04690413 -
NOWDx Test for the Detection of Antibodies to COVID-19
|
N/A |